Atogepant: clinical trials recruiting now
3
Recruiting trials
3
Conditions studied
24
US states with sites
18
Countries
FDA drug label
- FDA-approved
- Yes. Atogepant appears in the FDA drug-label database. Marketed as Qulipta.
- Drug class
- Calcitonin Gene-related Peptide Receptor Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Calcitonin Gene-related Peptide Receptor Antagonists (as stated on the FDA label)
FDA-approved use
QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
Phase breakdown
Phase 3 2
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Migraine · Atogepant for Migraine | 3 |
| Chronic Migraine | 2 |
| Episodic Migraine | 2 |
Recruiting trials involving Atogepant
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Common questions
Is Atogepant FDA-approved?
Yes, marketed as Qulipta.
How many recruiting trials involve Atogepant?
3 recruiting trials across 3 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.